| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3065251 | Journal of Neuroimmunology | 2009 | 4 Pages |
Abstract
We studied dendritic, myeloid (mDCs) (BDCA1+/CD19−) and plasmacytoid cells (pDCs) (BDCA2+/CD123+) and B-cells (CD19+) at relapse, after short intravenous methyloprednisolone therapy and 30 days after treatment completion (remission period) and results were compared with a control group of healthy volunteers. We confirmed the decrease in BDCA2+/CD123+ after therapy (p = 0.00006) and then an increase (p = 0.0032) in comparison to the control group. The level of B CD19+ cells after GC therapy increased compared to the control group (p = 0.00809) and had stabilised 30 days after therapy. The effect of methyloprednisolone on DC function and B-cell levels thus changes.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mitosek-Szewczyk Krystyna, Tabarkiewicz Jacek, Radej Sebastian, Belniak Ewa, Bartosik-Psujek Halina, Stelmasiak Zbigniew, Rolinski Jacek,